Bio-on spa

bio-on.it

Bio-On S.p.A., an Italian Intellectual Property Company (IPC), operates in the bioplastic sector conducting applied research and development of modern bio-fermentation technologies in the field of eco-sustainable and completely naturally biodegradable materials. In particular, Bio-On develops industrial applications through the creation of product characterizations, components and plastic items. Since February 2007, Bio-On S.p.A. has also been operating in the development of natural and sustainable chemicals for the future. Bio-On has developed an exclusive process for the production of a family of polymers called PHAs

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

BICYCLE THERAPEUTICS ANNOUNCES BT5528 PHASE I DOSE ESCALATION RESULTS IN PATIENTS WITH ADVANCED SOLID TUMORS

Bicycle Therapeutics | September 08, 2022

news image

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors. “The therapeutic profile from the dose escalation portion of the Phase I/II trial of BT5528 in patients with late-line disease suggests...

Read More

ENTERPRISE THERAPEUTICS NABS NOVARTIS VC EXEC AS NEW CMO

FierceBiotech | February 10, 2020

news image

Britain-based biotech Enterprise Therapeutics has hired Novartis Venture Fund managing director David Morris, M.D., as its next chief medical officer. Morris, who will continue to serve as the fund’s operating partner, will lead Enterprise’s development strategy and drive its two lead respiratory programs through the clinic. These are ETD002, a first-in-class TMEM16A potentiator, and ETD001, an ENaC blocker, both of which are hoping to help cystic fibrosis (CF) patients....

Read More

MedTech

SOLVIAS ACQUIRES CERGENTIS TO BOLSTER BIOLOGICS AND CELL & GENE THERAPY CAPABILITIES

Solvias | July 18, 2022

news image

Solvias, one of the world's leading independent pharmaceutical testing and manufacturing companies, announced today that it has acquired Utrecht, Netherlands-based Cergentis. The acquisition bolsters Solvias' platform of biologics and cell and gene therapy testing solutions. According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are projected to accelerate at a 63% compound annual growth rate through 2026. As more resear...

Read More

TWINSTRAND BIOSCIENCES LAUNCHES DUPLEX SEQUENCING TECHNOLOGY

BioSpace | February 25, 2020

news image

TwinStrand Biosciences™, a next-generation DNA sequencing technology company, today announced the launch of TwinStrand Duplex Sequencing™ Technology kits at the annual Advances in Genome Biology and Technology (AGBT) General Meeting in Marco Island, Florida. At launch, the company will offer their platform technology for two research applications: detection of minimal residual disease in acute myeloid leukemia patients (AML MRD) and a multi-species genetic toxicology assay for rapid ...

Read More
news image

Cell and Gene Therapy

BICYCLE THERAPEUTICS ANNOUNCES BT5528 PHASE I DOSE ESCALATION RESULTS IN PATIENTS WITH ADVANCED SOLID TUMORS

Bicycle Therapeutics | September 08, 2022

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, today announced Phase I dose escalation top-line results from its Phase I/II trial of BT5528, a BTC targeting EphA2, in patients with advanced solid tumors. “The therapeutic profile from the dose escalation portion of the Phase I/II trial of BT5528 in patients with late-line disease suggests...

Read More
news image

ENTERPRISE THERAPEUTICS NABS NOVARTIS VC EXEC AS NEW CMO

FierceBiotech | February 10, 2020

Britain-based biotech Enterprise Therapeutics has hired Novartis Venture Fund managing director David Morris, M.D., as its next chief medical officer. Morris, who will continue to serve as the fund’s operating partner, will lead Enterprise’s development strategy and drive its two lead respiratory programs through the clinic. These are ETD002, a first-in-class TMEM16A potentiator, and ETD001, an ENaC blocker, both of which are hoping to help cystic fibrosis (CF) patients....

Read More
news image

MedTech

SOLVIAS ACQUIRES CERGENTIS TO BOLSTER BIOLOGICS AND CELL & GENE THERAPY CAPABILITIES

Solvias | July 18, 2022

Solvias, one of the world's leading independent pharmaceutical testing and manufacturing companies, announced today that it has acquired Utrecht, Netherlands-based Cergentis. The acquisition bolsters Solvias' platform of biologics and cell and gene therapy testing solutions. According to pharmaceutical market intelligence provider, Evaluate, global sales of cell and gene therapies are projected to accelerate at a 63% compound annual growth rate through 2026. As more resear...

Read More
news image

TWINSTRAND BIOSCIENCES LAUNCHES DUPLEX SEQUENCING TECHNOLOGY

BioSpace | February 25, 2020

TwinStrand Biosciences™, a next-generation DNA sequencing technology company, today announced the launch of TwinStrand Duplex Sequencing™ Technology kits at the annual Advances in Genome Biology and Technology (AGBT) General Meeting in Marco Island, Florida. At launch, the company will offer their platform technology for two research applications: detection of minimal residual disease in acute myeloid leukemia patients (AML MRD) and a multi-species genetic toxicology assay for rapid ...

Read More

Resources

resource image

Cell and Gene Therapy

VIA Thaw™ automated dry thawer

Video

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

resource image

Cell and Gene Therapy

VIA Thaw™ automated dry thawer

Video

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us